Betaxolol
Product Images NDC 10135-623

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Betaxolol (NDC 10135-623). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Following Chemical Structure Of Betaxolol Is A β1-selective (cardioselective) Adrenergic Receptor Blocking Agent Available As 10-mg And 20-mg Tablets For Oral Administration. Betaxolol Is Chemically Described As 2-propanol,1-[4-[2- (cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-,hydrochloride,(±). (Betaxolol Tablets Usp Film Coated 01)

The Following Chemical Structure Of Betaxolol Is A β1-selective (cardioselective) Adrenergic Receptor Blocking Agent Available As 10-mg And 20-mg Tablets For Oral Administration. Betaxolol Is Chemically Described As 2-propanol,1-[4-[2- (cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-,hydrochloride,(±). (Betaxolol Tablets Usp Film Coated 01)
FDA Label Image

Betaxolol, Like Other Beta-blockers, Has Been Associated With The Development Of Antinuclear Antibodies (ana) (e.g., Lupus Erythematosus). In Controlled Clinical Studies, Conversion Of Ana From Negative To Positive Occurred In 5.3% Of The Patients Treated With Betaxolol, 6.3% Of The Patients Treated With Atenolol, 4.9% Of The Patients Treated With Propranolol, And 3.2% Of The Patients Treated With Placebo. Betaxolol Adverse Events Reported With A 2% Or Greater Frequency, And Selected Events With Lower Frequency, In U.s. Controlled Studies Are: (Betaxolol Tablets Usp Film Coated 02)

Betaxolol, Like Other Beta-blockers, Has Been Associated With The Development Of Antinuclear Antibodies (ana) (e.g., Lupus Erythematosus). In Controlled Clinical Studies, Conversion Of Ana From Negative To Positive Occurred In 5.3% Of The Patients Treated With Betaxolol, 6.3% Of The Patients Treated With Atenolol, 4.9% Of The Patients Treated With Propranolol, And 3.2% Of The Patients Treated With Placebo. Betaxolol Adverse Events Reported With A 2% Or Greater Frequency, And Selected Events With Lower Frequency, In U.s. Controlled Studies Are: (Betaxolol Tablets Usp Film Coated 02)
FDA Label Image

In Europe, The Placebo-controlled Study Lasted For 4 Weeks, While The Comparative Studies Had A 4-52- Week Double-blind Phase. The Following Doses Were Studied: Betaxolol 20 And 40 mg Once Daily And Atenolol 100 mg Once Daily. From European Controlled Hypertension Clinical Trials, The Following Adverse Events Reported By 2% Or More Patients And Selected Events With Lower Frequency Are Presented: (Betaxolol Tablets Usp Film Coated 03)

In Europe, The Placebo-controlled Study Lasted For 4 Weeks, While The Comparative Studies Had A 4-52- Week Double-blind Phase. The Following Doses Were Studied: Betaxolol 20 And 40 mg Once Daily And Atenolol 100 mg Once Daily. From European Controlled Hypertension Clinical Trials, The Following Adverse Events Reported By 2% Or More Patients And Selected Events With Lower Frequency Are Presented: (Betaxolol Tablets Usp Film Coated 03)
FDA Label Image

Principal Display Panelndc 10135-0623-01marlexbetaxololtablets, Usp10 mg100 Film Coated Tabletsrx Only (Betaxolol Tablets Usp Film Coated 04)

Principal Display Panelndc 10135-0623-01marlexbetaxololtablets, Usp10 mg100 Film Coated Tabletsrx Only (Betaxolol Tablets Usp Film Coated 04)
FDA Label Image

Principal Display Panelndc 10135-0624-01marlexbetaxololtablets, Usp20 mg100 Film Coated Tabletsrx Only (Betaxolol Tablets Usp Film Coated 05)

Principal Display Panelndc 10135-0624-01marlexbetaxololtablets, Usp20 mg100 Film Coated Tabletsrx Only (Betaxolol Tablets Usp Film Coated 05)